The industry remains unwavering in the commitment to increased clinical trial accessibility and representation.
During SCOPE 2025, Pam Tenaerts, chief science officer (at the time of the interview) at Medable, took time out of her schedule to discuss the importance of representation in clinical trials to ensure medicines are effective for diverse populations. Tenaerts stresses that that inclusive trials enhance patient trust in medications.
Key Takeaways
- The industry remains committed to maintaining high-quality, representative data from clinical trials.
- The industry is leaning more towards conducting clinical trials in locations where the target patient population is more prevalent, such as gastric carcinoma trials in Asia and melanoma trials in high sun exposure areas.
- Efforts are being made to include a wider network of clinical research sites, such as retail pharmacies and clinical practices, to improve patient access and representation.
- Reflecting the diversity of the patient population in clinical trials is important for building trust in the medications among both patients and clinicians.
ALL COVERAGE
Jay Ferro, EVP, CIO, CPO & CTO at Clario discusses safety, trust and what keeps him up at night.
Continuing our SCOPE 2025 coverage, Rohit Nambisan, CEO at Lokavant addresses not only current challenges, but the life sciences industry’s responsibility to maintain scientific integrity.
Elisa Cascade, CPO at Advarra explains why addressing the challenges faced by clinical research sites is vital for improving patient trust and the overall viability of clinical trials.
The industry remains unwavering in the commitment to increased clinical trial accessibility and representation.
As communication gaps in the US healthcare market widen, the emphasis on the need for credible information and patient empowerment is paramount.
While at SCOPE 2025, Sam Srivastava, CEO at WCG Clinical discusses the challenges and responsibilities of the life sciences industry in building public trust amidst growing anger towards healthcare.
In the current legal and political landscape, it is all about survival for DEI initiatives.
Konstantina Katcheves, Senior VP of Innovative Global Business Development at Teva Pharmaceuticals brings insights from the World Economic Forum to SCOPE 2025.
